PMID- 9189180
OWN - NLM
STAT- MEDLINE
DCOM- 19970702
LR  - 20220331
IS  - 0305-7372 (Print)
IS  - 0305-7372 (Linking)
VI  - 23
IP  - 1
DP  - 1997 Jan
TI  - Temozolomide: a review of its discovery, chemical properties, pre-clinical 
      development and clinical trials.
PG  - 35-61
FAU - Newlands, E S
AU  - Newlands ES
AD  - Department of Medical Oncology, Charing Cross Hospital, London, U.K.
FAU - Stevens, M F
AU  - Stevens MF
FAU - Wedge, S R
AU  - Wedge SR
FAU - Wheelhouse, R T
AU  - Wheelhouse RT
FAU - Brock, C
AU  - Brock C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Adult
MH  - Animals
MH  - *Antineoplastic Agents, Alkylating/chemistry/pharmacology
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Dacarbazine/*analogs & derivatives/chemistry/pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Experimental/drug therapy
MH  - Temozolomide
MH  - Tumor Cells, Cultured/drug effects
RF  - 106
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - S0305-7372(97)90019-0 [pii]
AID - 10.1016/s0305-7372(97)90019-0 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 1997 Jan;23(1):35-61. doi: 10.1016/s0305-7372(97)90019-0.